NMDA receptor partial agonist GLYX-13 alleviates chronic stress-induced depression-like behavior through enhancement of AMPA receptor function in the periaqueductal gray

Po-Sheng Yang,Hsien-Yu Peng,Tzer-Bin Lin,Ming-Chun Hsieh,Cheng-Yuan Lai,An-Sheng Lee,Hsueh-Hsiao Wang,Yu-Cheng Ho

DOI: https://doi.org/10.1016/j.neuropharm.2020.108269

IF: 5.273

2020-11-01

Neuropharmacology

Abstract:<p>Depression is a common mental disorder affecting more than 300 million people worldwide and is one of the leading causes of disability among all medical illnesses. The accumulation of preclinical data has fueled the revival of interest in targeting glutamatergic neurotransmission for the treatment of major depressive disorder. GLYX-13, a glutamatergic compound that acts as an <em>N</em>-methyl-<span class="small-caps">d</span>-aspartate (NMDA) modulator with glycine-site partial agonist properties, produces rapid and long-lasting antidepressant effects in both animal models and patients. However, the mechanisms underlying the antidepressant actions of GLYX-13 have not been fully characterized, especially in the midbrain ventrolateral periaqueductal gray (vlPAG), a brain stem area that controls stress-associated depression-like behavior. Here, we use a combination of electrophysiological recordings, behavioral tests, and pharmacological manipulations to study the antidepressant actions of GLYX-13 in the vlPAG. A single intravenous injection of a GLYX-13 rapidly mitigated footshock stress (FS)-induced depression-like behavior in rats. The FS-induced diminished glutamatergic transmission in the vlPAG was also reversed by a single GLYX-13 intravenous injection. Moreover, intra-vlPAG GLYX-13 microinjection produced a long-lasting antidepressant effect; however, this effect was prevented by the intra-vlPAG microinjection of tropomyosin-related kinase B (TrkB) receptor antagonist ANA-12, a selective mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, and CNQX, an AMPA receptor antagonist. Additionally, a bath application of GLYX-13 enhanced glutamatergic transmission in vlPAG neurons; however, this enhancement effect was blocked by the co-application of ANA-12 and rapamycin. These results demonstrate that BDNF-TrkB-mTORC1 signaling in the vlPAG is required for the sustained antidepressant effects of GLYX-13.</p>

pharmacology & pharmacy,neurosciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: whether GLYX - 13 (a partial agonist of NMDA receptor) can relieve depressive - like behaviors caused by chronic stress by enhancing AMPA receptor function in the ventrolateral periaqueductal gray (vlPAG).

Specifically, the researchers focused on the following aspects:
1. **The influence of GLYX - 13 on depressive - like behaviors caused by chronic stress**: Evaluate the role of GLYX - 13 in relieving depressive - like behaviors induced by chronic foot - shock stress (FS) through behavioral tests (such as forced - swim test and female rat urine - sniffing test).
2. **The influence of GLYX - 13 on glutamatergic transmission in vlPAG**: Study whether GLYX - 13 can reverse the attenuation of glutamatergic transmission in vlPAG caused by chronic stress through electrophysiological recording techniques.
3. **The mechanism of action of GLYX - 13**: Explore whether GLYX - 13 exerts an antidepressant effect in vlPAG through the BDNF - TrkB - mTORC1 signaling pathway. The researchers used the TrkB receptor antagonist ANA - 12, the mTORC1 inhibitor rapamycin and the AMPA receptor antagonist CNQX for pharmacological intervention to verify this mechanism.

In conclusion, this study aims to comprehensively reveal the role of GLYX - 13 in relieving depressive - like behaviors caused by chronic stress and its potential neurobiological mechanisms.